Drugs / RO7303509
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05462522 | Jan 2023 → Jul 2025 | systemic sclerosis | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7303509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462522 ↗ |
| Route | Subcutaneous | “as SC injection monthly” NCT05462522 ↗ |